JP2021521138A5 - - Google Patents

Info

Publication number
JP2021521138A5
JP2021521138A5 JP2020555218A JP2020555218A JP2021521138A5 JP 2021521138 A5 JP2021521138 A5 JP 2021521138A5 JP 2020555218 A JP2020555218 A JP 2020555218A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2021521138 A5 JP2021521138 A5 JP 2021521138A5
Authority
JP
Japan
Prior art keywords
methyl
tetrahydro
oxy
sulfonyl
pyrrolo
Prior art date
Application number
JP2020555218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521138A (ja
JPWO2019210828A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/085001 external-priority patent/WO2019210828A1/en
Publication of JP2021521138A publication Critical patent/JP2021521138A/ja
Publication of JP2021521138A5 publication Critical patent/JP2021521138A5/ja
Publication of JPWO2019210828A5 publication Critical patent/JPWO2019210828A5/ja
Priority to JP2024094048A priority Critical patent/JP7540113B1/ja
Priority to JP2024135320A priority patent/JP7688210B2/ja
Priority to JP2025085498A priority patent/JP2025119001A/ja
Withdrawn legal-status Critical Current

Links

JP2020555218A 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤 Withdrawn JP2021521138A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024094048A JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018085217 2018-04-29
CNPCT/CN2018/085217 2018-04-29
CN2018107134 2018-09-21
CNPCT/CN2018/107134 2018-09-21
PCT/CN2019/085001 WO2019210828A1 (en) 2018-04-29 2019-04-29 Bcl-2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094048A Division JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤

Publications (3)

Publication Number Publication Date
JP2021521138A JP2021521138A (ja) 2021-08-26
JP2021521138A5 true JP2021521138A5 (https=) 2022-04-22
JPWO2019210828A5 JPWO2019210828A5 (https=) 2022-04-22

Family

ID=68386968

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555218A Withdrawn JP2021521138A (ja) 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Country Status (22)

Country Link
US (3) US11420968B2 (https=)
EP (2) EP3788042B1 (https=)
JP (4) JP2021521138A (https=)
KR (1) KR102738032B1 (https=)
CN (3) CN117683029A (https=)
AU (1) AU2019264475C1 (https=)
BR (1) BR112020022092A2 (https=)
CA (1) CA3098348A1 (https=)
DK (1) DK3788042T3 (https=)
ES (1) ES3018793T3 (https=)
FI (1) FI3788042T3 (https=)
HR (1) HRP20250392T1 (https=)
HU (1) HUE071493T2 (https=)
IL (1) IL278366B2 (https=)
LT (1) LT3788042T (https=)
MX (2) MX2020011495A (https=)
PL (1) PL3788042T3 (https=)
PT (1) PT3788042T (https=)
SG (1) SG11202009933WA (https=)
SI (1) SI3788042T1 (https=)
TW (1) TWI855062B (https=)
WO (1) WO2019210828A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HUE060310T2 (hu) 2017-04-18 2023-02-28 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-indukáló szerek
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
SI3788042T1 (sl) * 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
KR20220100992A (ko) 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
JP7839962B2 (ja) * 2020-04-15 2026-04-03 ビーワン メディシンズ ワン ゲーエムベーハー Ｂｃｌ－２阻害剤
EP4146649A4 (en) * 2020-05-08 2024-09-11 Fochon Biosciences, Ltd. COMPOUNDS AS BCL-2 INHIBITORS
CN114478520B (zh) * 2020-10-28 2025-01-10 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN117642157A (zh) * 2021-03-19 2024-03-01 伊尔治疗学股份有限公司 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
EP4351542A4 (en) * 2021-06-02 2025-04-09 BeiGene Switzerland GmbH Method for treating B-cell malignancy with BCL-2 inhibitor
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
CA3230314A1 (en) * 2021-08-31 2023-03-09 Beigene Switzerland Gmbh Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
US20250122191A1 (en) * 2021-11-20 2025-04-17 Fochon Biosciences, Ltd Compounds as bcl-2 inhibitors
EP4442685A4 (en) * 2021-12-06 2025-11-19 Hangzhou Healzen Therapeutics Co Ltd BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES
TW202400163A (zh) 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
CN119365456A (zh) * 2022-06-01 2025-01-24 重庆复创医药研究有限公司 作为bcl-2抑制剂的化合物
CN119584963A (zh) * 2022-07-21 2025-03-07 百济神州(苏州)生物科技有限公司 使用bcl-2抑制剂治疗多发性骨髓瘤的方法
WO2024140690A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. Intermediates of sonrotoclax and the method of preparing the same
AU2023416871A1 (en) * 2022-12-27 2025-08-14 Beone Medicines I Gmbh Salts and solid forms of sonrotoclax intermediate
WO2024140678A1 (en) * 2022-12-27 2024-07-04 Beigene (Suzhou) Co., Ltd. A ketal protected intermediate for sonrotoclax and preparation method thereof
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof
WO2026019442A1 (en) * 2024-07-14 2026-01-22 Eil Therapeutics, Inc. Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2577752A1 (en) 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
WO2006127364A1 (en) 2005-05-24 2006-11-30 Abbott Laboratories Apoptosis promoters
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
CN102112445B (zh) 2008-06-09 2014-06-18 百时美施贵宝公司 作为抗细胞凋亡Bcl抑制剂的羟基苯基磺酰胺
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
AU2009326259A1 (en) 2008-12-08 2011-07-28 Boehringer Ingelheim International Gmbh Compounds for treating cancer
CN102282129A (zh) 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282128B (zh) 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
NZ595708A (en) * 2009-05-26 2014-03-28 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011029842A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
SG192126A1 (en) 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
CN104039797B (zh) 2011-10-12 2016-06-01 南京奥昭生物科技有限公司 作为细胞凋亡诱导剂的杂环分子
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
MX2014007732A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
BR112014015442A8 (pt) 2011-12-23 2017-07-04 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
KR102318204B1 (ko) 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
WO2018041248A1 (zh) 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HUE060310T2 (hu) 2017-04-18 2023-02-28 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-indukáló szerek
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Similar Documents

Publication Publication Date Title
JP2021521138A5 (https=)
IL278366B1 (en) BCL-2 inhibitors
JPWO2019210828A5 (https=)
US11878975B2 (en) Substituted indole compounds useful as TLR inhibitors
JP2014506929A5 (https=)
AR119209A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
JP6532474B2 (ja) ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用
GB2609879A (en) Antagonists of the adenosine A2a receptor
JP2017531672A5 (https=)
CA2623982A1 (en) Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
RU2013126657A (ru) Ингибиторы nampt и rock
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
HRP20150269T1 (hr) Inhibitori beta-laktamaze
JP2011511003A5 (https=)
JP2018503674A5 (https=)
JP2017505327A5 (https=)
CA2393809A1 (en) Heterocyclic dihydropyrimidines as potassium channel inhibitors
RU2010116759A (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
JP2017524007A5 (https=)
RU2017117248A (ru) Этил-n-boc-пиперидинил-пиразоло-пиридоны в качестве ингибиторов янус-киназы
JP2018530557A5 (https=)
RU2004121166A (ru) 2-аминобензотиазолилмочевины в качестве модуляторов аденозина
JP2015526395A5 (https=)
JP2015537010A5 (https=)
RU2010123923A (ru) Производные изоксазоло-пиридина